Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RPRX: Endo schedule...
Nerf, sounds like from your post that RPRX may need another few weeks to wrap up endo 6 mo trial results. Are we now antcipating first week in June for top line results? I'm assuming Androxal come mid-late June as do the safety for Endo trial.
T.i.a
Two weeks to go, IMO, until we see more information and the picture gets clearer.
Nerf, have you heard any updates on when the endo results will be out? I think according to your last report from JP it was near the end of May, which is 6 days away.
thanks
GTCB - seems like it would make sense for the company to do a 5-1 reverse split to raise the share price, while decreasing the shares outstanding (and float). This could bring them into the price range where more funds can buy them imo.
JAV
rfj, anything of interest (new) at the presentation? If so I'll check it out.
T.i.a.
LOL, and your opinion is more well researched than rfj, Thomas or others that have worked hard to uncover information on RPRX? RPRX's road isn't going to be long and slow, it will be over within the next 12-18 months for good or bad. Unlike most other biotechs that you may have suffered with.
Thanks alert. I read his message too fast, and that makes sense to me.
Thomas, so you don't believe the final endo Proellex results, androxal results in June, and safety data on Proellex (assuming all are good) are not enough to move RPRX above $15 by June-July, let alone Aug period? I would hope so, but I'm not willing to make any bets around the Aug 15 options either way. I just believe that if this news is positive we could be bumped up to the 15-17 region by August. Thanks!
Then why have a panel? Are all these PhD's and MD's considered non-essential? Hmmm!
pre_clinical, I also have the same view as you do, in terms of M. Gold trying to get better terms for Provenge approval.
Thanks!
No, the opposite.
LOL, that's from 8/8/06 conf call. Situations have changed, and so will DNDN's willingness to negotiate some kind of partner prior to another FDA look. People still forget the 13-4 vote for DNDN by the panel. I realize they need to hit the mark with 9902b, but thats where one makes their risk/reward calculation and then places their bet.
Geoff, my opinion too! Thanks! EOM
I love Cramer.
Dendreon (DNDN - Cramer's Take - Stockpickr - Rating): "At this point, this thing is such a battleground, I say don't buy."
I'm getting some many nice contrarian indicators popping up all over the place. Poor Cramer doesn't know how to play risk/reward imo. ;)
http://www.thestreet.com/_yahoo/funds/lightninground/10358389_2.html
Jon, imo DNDN will issue a secondary prior to an interim look at 9902b next year. Could occur right after an Ex-US partnership deal. Just my inference from what I heard on the DNDN conf call. I think too many people are being retrospective with DNDN and not prospective with their potential in the next 12 months, and beyond. Many of you may miss another birds nest on the ground. So far I've done well with REGN, RPRX and recently GNVC. And DNDN! ;) Don't get lost in the trees. The forest is clearly visible.
Good luck!
Spartex
Clark,
In some respects, many (even longs) have also written off DNDN after their approvable letter. The problem is that they became super bulls and went crazy buying shares in the $15+ price range which wasn't prudent. However, those who were deft could buy DNDN shares in the low $5's the morning after the FDA news. Price entry is one of the key decision points that an investor needs to make, not necessarily whether they will buy or not buy a particular company.
Regards,
Spartex
Bio_Pete, you are correct. RPRX ran up the day before fibroids news came out. We'll see if the pattern holds, but I would hope that management keeps their lips tight accordingly.
Nerf-- LOL! Funds are just buying back in after options expiration. Time for them to fish or cut bait. I think they are fishing but the price of bait just went up! ;)
Dendreon Announces Presentation of Data at American Urological Association Annual Meeting
Sunday May 20, 6:30 pm ET
-Data May Support Use of PROVENGE(R) as Front-line Treatment in Advanced Prostate Cancer-
SEATTLE and ANAHEIM, Calif., May 20 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN - News) today announced the presentation of data from an analysis of Phase 3 Studies (D9901 and D9902A) that showed a prolonged survival benefit for patients who were initially treated with PROVENGE (sipuleucel-T) who then went on to receive docetaxel chemotherapy after disease progression. The data were presented today at the American Urological Association (AUA) Annual Meeting in Anaheim, California.
The abstract, titled "Advanced Prostate Cancer Patients who Receive Sipuleucel-T followed by Docetaxel Have Prolonged Survival" (#605), authored by Daniel P. Petrylak, M.D., associate professor of medicine at New York- Presbyterian Hospital at the Columbia University Medical Center, is based on an exploratory analysis conducted to assess the influence of the active cellular immunotherapy PROVENGE on the clinical outcome of patients who subsequently went on to receive docetaxel chemotherapy after primary treatment with PROVENGE. The analysis was conducted by evaluating data from two Phase 3 clinical trials of PROVENGE in patient with asymptomatic, metastatic, androgen-independent prostate cancer (AIPC).
"The results of this analysis suggest that the use of sipuleucel-T as a first-line treatment followed by the chemotherapy docetaxel upon disease progression may provide patients with a substantially prolonged survival benefit," said Dr. Petrylak. "This analysis provides valuable clinical insight as to how the treatment of men with advanced prostate cancer will likely evolve with the potential introduction of new products like sipuleucel- T that complement the currently available treatment regimens for men with advanced prostate cancer."
Study Design and Results
This analysis was conducted by evaluating data from two identically designed randomized Phase 3 trials (D9901 and D9902A; n=225) conducted in men with asymptomatic, metastatic, androgen independent prostate cancer. Survival analyses were performed on the subgroup of 82 patients in the trials that were documented to have received docetaxel chemotherapy following initial treatment with either PROVENGE or placebo.
According to the analysis, the patients who received initial treatment with PROVENGE followed by docetaxel had a median survival of 34.5 months compared to 25.4 months for those patients in the placebo arm who received treatment with docetaxel chemotherapy, a 9.1 month difference. In addition, an analysis of overall survival demonstrated that patients in the PROVENGE arm who received subsequent therapy with docetaxel had a 47 percent reduction in their risk of death compared to those in the placebo arm who received subsequent therapy with docetaxel (HR = 1.90, p-value = 0.023).
About Prostate Cancer
Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than one million men in the United States have prostate cancer, with an estimated 218,890 new cases expected to be diagnosed in 2007, and more than 27,000 men expected to die this year from the disease.
About PROVENGE
PROVENGE (sipuleucel-T) is an investigational product that may represent the first in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to stimulate a patient's own immune system. PROVENGE is in late-stage clinical development for the treatment of patients with early-stage and advanced prostate cancer. In clinical studies, patients typically received three infusions over a one-month period as a complete course of therapy.
About Dendreon
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has headquarters in Seattle and is traded on The Nasdaq Stock Market® under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.
Except for historical information, this news release contains forward- looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of a clinical trial for PROVENGE will not support our biologics license application, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a biologics license application for a therapeutic, the risk that the results of existing clinical trials data or from additional clinical trials for PROVENGE or other products may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.
--------------------------------------------------------------------------------
Source: Dendreon Corporation
http://biz.yahoo.com/prnews/070520/clsu010.html?.v=9
Dendreon Announces Presentation of Data at American Urological Association Annual Meeting
Sunday May 20, 6:30 pm ET
-Data May Support Use of PROVENGE(R) as Front-line Treatment in Advanced Prostate Cancer-
SEATTLE and ANAHEIM, Calif., May 20 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN - News) today announced the presentation of data from an analysis of Phase 3 Studies (D9901 and D9902A) that showed a prolonged survival benefit for patients who were initially treated with PROVENGE (sipuleucel-T) who then went on to receive docetaxel chemotherapy after disease progression. The data were presented today at the American Urological Association (AUA) Annual Meeting in Anaheim, California.
The abstract, titled "Advanced Prostate Cancer Patients who Receive Sipuleucel-T followed by Docetaxel Have Prolonged Survival" (#605), authored by Daniel P. Petrylak, M.D., associate professor of medicine at New York- Presbyterian Hospital at the Columbia University Medical Center, is based on an exploratory analysis conducted to assess the influence of the active cellular immunotherapy PROVENGE on the clinical outcome of patients who subsequently went on to receive docetaxel chemotherapy after primary treatment with PROVENGE. The analysis was conducted by evaluating data from two Phase 3 clinical trials of PROVENGE in patient with asymptomatic, metastatic, androgen-independent prostate cancer (AIPC).
"The results of this analysis suggest that the use of sipuleucel-T as a first-line treatment followed by the chemotherapy docetaxel upon disease progression may provide patients with a substantially prolonged survival benefit," said Dr. Petrylak. "This analysis provides valuable clinical insight as to how the treatment of men with advanced prostate cancer will likely evolve with the potential introduction of new products like sipuleucel- T that complement the currently available treatment regimens for men with advanced prostate cancer."
Study Design and Results
This analysis was conducted by evaluating data from two identically designed randomized Phase 3 trials (D9901 and D9902A; n=225) conducted in men with asymptomatic, metastatic, androgen independent prostate cancer. Survival analyses were performed on the subgroup of 82 patients in the trials that were documented to have received docetaxel chemotherapy following initial treatment with either PROVENGE or placebo.
According to the analysis, the patients who received initial treatment with PROVENGE followed by docetaxel had a median survival of 34.5 months compared to 25.4 months for those patients in the placebo arm who received treatment with docetaxel chemotherapy, a 9.1 month difference. In addition, an analysis of overall survival demonstrated that patients in the PROVENGE arm who received subsequent therapy with docetaxel had a 47 percent reduction in their risk of death compared to those in the placebo arm who received subsequent therapy with docetaxel (HR = 1.90, p-value = 0.023).
About Prostate Cancer
Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than one million men in the United States have prostate cancer, with an estimated 218,890 new cases expected to be diagnosed in 2007, and more than 27,000 men expected to die this year from the disease.
About PROVENGE
PROVENGE (sipuleucel-T) is an investigational product that may represent the first in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to stimulate a patient's own immune system. PROVENGE is in late-stage clinical development for the treatment of patients with early-stage and advanced prostate cancer. In clinical studies, patients typically received three infusions over a one-month period as a complete course of therapy.
About Dendreon
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has headquarters in Seattle and is traded on The Nasdaq Stock Market® under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.
Except for historical information, this news release contains forward- looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of a clinical trial for PROVENGE will not support our biologics license application, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a biologics license application for a therapeutic, the risk that the results of existing clinical trials data or from additional clinical trials for PROVENGE or other products may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.
--------------------------------------------------------------------------------
Source: Dendreon Corporation
http://biz.yahoo.com/prnews/070520/clsu010.html?.v=9
Bio_Pete, I've learned from a number of other people (from message boards of stocks I follow) that during expiration stocks will gravitate to the strike price which benefits those who have sold calls and/or puts. I haven't noticed RPRX following this pattern at all the past few months, so I didn't give it much attention. Plus, they have news pending in May sometime soon. It wasn't until I noticed RPRX dropping on low volume (below 13) and heading towards 12.5 that the options expiration was going to have an effect. I agree, it would have been nice selling some in the low 13's, and buying back in the low 12's a few days later. Why not!
Haven't bought any AIS yet, but I'm following them. Thanks also for your other names...which I will put on my stocks to watch (hope they recover!). I am only holding around 5 biotechs at the moment and try to keep it focused as I find it too hard to track more than 5 at a time closely, as well as a list of new candidates. Currently RPRX, DNDN (sold 1/2 my position at 21's!), REGN, GNVC, and a little SGEN.
I agree with your estimate for current fair value of RPRX, and this is in line with rfj's valuation. May the next few PR's put this all to rest.
Bio_pete, it still sounds like you are doing ok with your evaluation of promising biotech companies and price-points you are using to build a position.
Looks like old RPRX will finish the day out at the 12.5 strike as I had anticipated. Awaiting the next PR on endo like every other long here. ;)
LOL. That depends on what "it" is, and what "country" you are going to be running from. Oh, and who is to blame for "it being over"? FDA is just doing a political move. Let 9902b stand on its own. It is validates the first PIII, DNDN is in the green. Question for me is if and how many shares I decided to accumulate based on price action.
apljack,
Thanks for that info. I think the idea is feasible. I remember folks within my workplace going to "wellness" programs which were run at a gym on site. I believe they focused on exercise and diet, so the idea isn't unique. I would just love to use this approach to deal with the growing type II diabetes population (children and adults), and I believe your mention of "behavioral health psychologists" would be one of the specialists needed to make this work. These diabetics need to have their behavior/habits rewired to include improved diet and a consistent exercise program. As a type I diabetic, my relatively strict diet and regular exercise have allowed me to control my blood sugars and thereby avoid any diabetic complications the past 20 years.
Geron Scientists and Collaborators Differentiate Human Embryonic Stem Cells Into Insulin-Producing Islet-Like Clusters
Thursday May 17, 7:30 am ET
Studies Demonstrate Feasibility of Producing Therapeutic Cells From hESCs for Treatment of Diabetes
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN - News) today reported that its scientists and collaborators at the University of Alberta have differentiated human embryonic stem cells (hESCs) into islet-like clusters (ILCs) that secrete insulin in response to elevated glucose levels. The studies demonstrate the feasibility of producing therapeutic cell types from hESCs for the treatment of diabetes.
To be published in the August issue of Stem Cells, which is available now for online viewing in Stem Cells Express at http://stemcells.alphamedpress.org/papbyrecent.dtl, the paper describes studies showing how the researchers differentiated hESCs into cell clusters containing the main cellular components of the islets of Langerhans. The islets of Langerhans are structures in the pancreas that are responsible for regulating and producing insulin in response to changing glucose concentrations and are targets for autoimmune destruction or dysfunction in Type I Diabetes.
"These studies show that the islet-like clusters contain the major cellular components of islets and are sensitive to glucose, the key sugar to which they must respond to be therapeutically beneficial," stated Anish Majumdar, Ph.D., the senior author of the paper. "Our major goal moving forward is to improve the purity, yield and maturational status of these cells to induce normoglycemia in animal models of diabetes."
Geron Corporation was granted U.S. Patent No. 7,033,831 in April 2006 covering the production of insulin-secreting cells from hESCs as well as two U.K. patents covering similar production methods. Geron also has a worldwide exclusive commercial license covering hESC-derived islets from the Wisconsin Alumni Research Foundation.
Geron's scientists and collaborators produced ILCs containing individual cells types that express insulin, glucagon and somatostatin, three of the major hormones produced by islet beta, alpha and delta cells, respectively. Further analysis of the insulin-producing cells indicates they also produce c-peptide, a peptide cleaved upon secretion of the precursor of insulin, indicating that insulin was actually produced, and not absorbed, by the cells. Approximately 2%-8% of the differentiated cells contain insulin and c-peptide and their insulin content was higher than that of fetal islets.
The ILCs functioned to secrete insulin in response to elevated glucose levels. Cells within the ILCs contained secretory granules characteristic of those seen in islet beta cells. In cell culture, the ILCs produced c-peptide and insulin when exposed to higher concentrations of glucose with the kinetics of an immature islet.
The protocol to produce the ILCs drives hESCs through a series of cell culture steps that mimic the progressive differentiation stages during development of the pancreas in humans. Other pancreatic cell types resembling those of the exocrine pancreas were also observed during the differentiation process. The protocol does not utilize serum or feeder cells of any kind, underscoring the scalability of the process.
Originally developed at the University of Alberta, the Edmonton Protocol provides the proof of concept that transplantation of purified cadaveric islets can significantly reduce the need for insulin in patients with advanced Type 1 Diabetes. Problems limiting the accessibility of transplantation therapy for diabetes patients are the poor availability of organs from cadavers and the eventual failure of the grafts, which often require replacement and chronic immunosuppression.
"The Edmonton Protocol provides significant evidence that transplantation of primary islets can be used to successfully reduce the need for insulin in patients with Type 1 Diabetes," said Thomas B. Okarma, Ph.D., M.D., Geron's president and chief executive officer. "It is the work published today that demonstrates the potential of human embryonic stem cells to enable the ready availability of uniform, functional islet cells for therapeutic administration."
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell-based therapeutics, with its spinal cord injury treatment anticipated to be the first product to enter clinical development. For more information, visit www.geron.com.
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Geron's human embryonic stem cell technology constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Geron's periodic reports, including the quarterly report on Form 10-Q for the quarter ended March 31, 2007.
Contact:
Geron
David L. Greenwood, 650-473-7765
Chief Financial Officer
info@geron.com
or
Russo Partners, LLC
David Schull, 858-717-2310 (Media)
david.schull@russopartnersllc.com
Matthew Haines, 212-845-4235 (Investors)
matthew.haines@russopartnersllc.com
--------------------------------------------------------------------------------
Source: Geron Corporation
http://biz.yahoo.com/bw/070517/20070517005178.html?.v=1
Diabetes drugs: I think I should start a personal health consulting business which addresses diet, exercise and health management. This would take care of 90+% of these diabetic issues. If I could hire a bunch of qualified specialists at a reasonable salary, I'd be good to go. Work within existing gyms, etc, to keep overhead low and charge reasonable fees. Start small, and then grow it like SBUX! ;)
I hope you realize that my idea is actually serious. However, I need the seed $$$ to evolve the concept and health care providers and/or employers to subsidize the costs.
I think these dogs are playing the 12.5 strike for options, as I stated yesterday. The volume is low and there isn't any strong interest up or down with volume today. Yesterday appeared to be the day where they knocked the stock price below 12.5 and I believe it will stay around that area through Friday. I'm be happy to see a positive PR break this up! ;)
Anyone attend today's Annual Meeting in NYC?
If so, any news tidbits of interest?
thanks
RPRX May Options: looks like someone wants the 12.5 calls to expire worthless by this Friday. Hmmmm!
Thank you very much Bio_pete! EOM
OT: xrymd, re: AIS
Do you still think it is reasonably priced as a "buy" at current levels? And thoughts on this company's trials over the next 6 months or so.
Thanks!
AIS - Thomas are you still long this stock, and if so do you find it attractive at current price?
T.i.a.
InSightec Ltd. - thanks Dew for that link.
Sounds interesting, but they've only used it on 3000 patients since 2004 FDA approval. I think the Proellex pill will be a much easier option (no need for going to Dr's office once prescribed) if it can get approval than using this ExAblate® system.
<<On 4-5-07, FrontPoint Partners owned 562k shares
and there is no mention of Morgan Stanley.
If they are the one and the same, it means they went
from owning 78k shares to owning 562k shares and down to 0
in a matter of 6 months. If they are not, it still means
they accumulated 562k shares and sold it all in a few months.>>
On April 5, RPRX was priced at 10.49 (close), and a little over a month later it is priced near 13. One would think that FrontPoint may have profited from their purchase of RPRX shares below 10.5, and if they had bought them higher (12.5's) in Jan-Feb they would have sold them by end of March quarter (right, if at a loss?). So one can speculate that they were up 25-30% with their investment and therefore sold as RPRX rose during April and early May. In fact, their sales really didn't have any overhang on RPRX price, as it rose 25%. Fast money in, fast money out. I hope the new buyers are "holders" so we can kick it up a bit more. ;)
http://www.stockta.com/cgi-bin/analysis.pl?symb=RPRX&num1=9&cobrand=&mode=stock
It looks like the buyers of the stock are slowing down the past few weeks and are awaiting endo trial results before buying more aggressively. Would be nice to get endo news before the annual meeting so there is more to talk about.
Biodel
http://www.biodel.com/about/overview.htm
The PIII trials are for a rapid-acting injectable insulin that (their angle) may work faster in a person's body than the leading Humalog insulin. fyi, I use Humalog and it usually works within 20-30 min which is good for me. I guess once could say if you can eat 10 min after a shot that is even "better". But it leaves you little time to shoot up and eat. In other words, you would probably start your meal right after taking your shot. The key is that they can compete in a $2 bil/year+ market for fast-acting insulins.
Their other product in PI is for a oral tablet formulation of insulin. "Biodel is also conducting a Phase I clinical trial evaluating VIAtab™, an oral (sublingual) tablet formulation of insulin." This one I believe would really have the killer advantage if it works and was approved. It would allow diabetics to take their insulin using a tablet rather than shots, or the inconvenient Eruba bong inhalent. May even compete with the slower acting insulins. I need to study this company further to find out how much of a market advantage it may have as well as its competitors.
Thanks StockAnalyzer regarding RPRX.
I believe the money flow trend will reverse based on nearterm news (if its what we longs anticipate). I appreciate your help in pointing out this aspect of the TA for RPRX, as well as the charts and resistance annotations.
One follow-up question. From your experience, is it normal to see moneyflow trend slow down after substantive news releases from biotech companies......where funds are waiting for the next flow of information to create more buying?
Regards,
Spartex
Hi Tony, Q on RPRX chart
Can you give me your thoughts regarding the chart (TA) of RPRX? I've been long since the $6's, and accumulated more in the 9's and 10's. Company will be releasing some trial results in around a week, which we believe will be consistent with positive Dec. interim results.
Thanks!
Since so many people believe in Provenge, you would think that someone could establish a foundation to fund compassionate use of Provenge for some prostate patients. I realize you need a person with resources and connections to wealthy individuals/foundations to help set up such a fund, but it is a thought that came to my mind. Does compassionate use have to be funded ONLY by the company (DNDN)? Can someone else provide the $$$?
I'm very sorry to hear that DNDN didn't actually go to the market to raise another $80 mil dollars by selling 5 mil shares when the stock was in the $17 dollar range. Would have been a prudent measure (what I was hoping for). So what happened? Did Mitch not listen to his CFO?? I have no idea. I sold have of my position in $21's as a measure of prudence and it paid off. Oh well.
RPRX afterhours
Bio_Pete, what's with these 100 share afterhour trades for RPRX 92 cents above the close?? You also mentioned that these premarket trades above $13 were meaningful for the direction of RPRX stock. Thoughts??
Otherwise, the trend is your friend!
Is RPRX having a stealth rally?
I would call it a stealth accumulation, but it isn't stealth to those of us who own the stock. Between what dewophile, Nerf, rfj and others have stated on this thread, as well as those on RPRX board, there isn't much more to say at this time.
The stock is very undervalued, and it may only be 12 months before they are bought out. I consider that a very short timeline from a biotech point of view.
Regards,
Spartex
Dew, thanks for your earlier reply, and also reference to your Testim results (compared to Androgel) back in Dec 06. I sort of agree with rfj that it makes sense to compare Androxal to the current leader in the field, but it would be nice to also have had a comparison to Testim (but the company is controlling their $$$ carefully) which has better efficacy than Androgel.
rfj's reply back to you here sounds very reasonable to me.
http://www.investorshub.com/boards/replies.asp?msg=15698871